Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Biogen delivered a strong result and managed an all-around beat last quarter.</li><li>The last quarter saw decreased total revenue, but the company delivered a solid performance overall.</li><li>The decline in Multiple Sclerosis (MS) product revenues was due to generic entrants for TECFIDERA and intense competition in the MS market.</li></ul>

Biogen delivered a strong result and managed an all-around beat last quarter.The last quarter saw decreased total revenue, but the company delivered a solid performance overall.The decline in Multiple Sclerosis (MS) product revenues was due to generic entrants for TECFIDERA and intense competition in the MS market.

Biogen Inc: Job Cuts to Prioritize New Drug Launches. Genius or Misstep? – Key Drivers

<ul><li>Biogen had a successful first quarter with an all-around beat.</li><li>The company executed the launch of Leqembi, an immediate transformative product in the Alzheimer's disease therapeutic area.</li><li>Biogen has been experiencing a lot of competition, making it necessary to think about how to grow the business in the future.</li></ul>

Biogen had a successful first quarter with an all-around beat.The company executed the launch of Leqembi, an immediate transformative product in the Alzheimer's disease therapeutic area.Biogen has been experiencing a lot of competition, making it necessary to think about how to grow the business in the future.

Biogen Inc.: The Lecanemab Progress On The Alzheimer’s Front & Other Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> is well-positioned to report double-digit revenue and profit growth through FY25, driven by strong performance of existing business and new growth engines.</li>
<li>CSL will launch FDA-approved gene therapy Hemgenix for Hemophilia B in the US in 2H23. With estimated global annual peak sales of $2.4B, Hemgenix is a compelling opportunity for CSL.</li>
<li>During H1FY23, CSL reported record level of plasma collections, with 36% growth in                volume. Current plasma collection is 10% above the pre-pandemic. Higher volume and yield will improve profitability.</li>
</ul>



CSL Ltd (CSL AU) is well-positioned to report double-digit revenue and profit growth through FY25, driven by strong performance of existing business and new growth engines.
CSL will launch FDA-approved gene therapy Hemgenix for Hemophilia B in the US in 2H23. With estimated global annual peak sales of $2.4B, Hemgenix is a compelling opportunity for CSL.
During H1FY23, CSL reported record level of plasma collections, with 36% growth in                volume. Current plasma collection is 10% above the pre-pandemic. Higher volume and yield will improve profitability.


CSL Ltd (CSL AU): Looking into New Engines for Sustainable and Profitable Growth

<ul><li>Biogen delivered an all-around beat in the last result.</li><li>TECFIDERA generic competition, ongoing interferon declines and some pricing pressure mostly brought on this reduction.</li><li>Based on these positive results, they started the Phase II/III AMETHYST investigation of litifilimab in CLE.</li></ul>

Biogen delivered an all-around beat in the last result.TECFIDERA generic competition, ongoing interferon declines and some pricing pressure mostly brought on this reduction.Based on these positive results, they started the Phase II/III AMETHYST investigation of litifilimab in CLE.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> is expected to report strong Q4 results, with double-digit revenue growth. Partial operation of Plant 4 will impact profitability, which will be continued through H12023.</li>
<li>The Chairman of the company has been selling shares, causing recent pullback in the stock, which should be considered as an attractive entry point.</li>
<li>The long-term growth story remains intact, with all eyes being on upcoming conference where the company may unfold its capex plan amid stellar order book and industry demand.</li>
</ul>



Samsung Biologics (207940 KS) is expected to report strong Q4 results, with double-digit revenue growth. Partial operation of Plant 4 will impact profitability, which will be continued through H12023.
The Chairman of the company has been selling shares, causing recent pullback in the stock, which should be considered as an attractive entry point.
The long-term growth story remains intact, with all eyes being on upcoming conference where the company may unfold its capex plan amid stellar order book and industry demand.


Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts

United States

Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biogen Inc (BIIB US)

Biogen Inc: Job Cuts to Prioritize New Drug Launches. Genius or Misstep? – Key Drivers

Biogen delivered a strong result and managed an all-around beat last quarter. The last quarter saw decreased total revenue, but the company...

Baptista Research

Biogen Inc.: The Lecanemab Progress On The Alzheimer’s Front & Other Drivers

Biogen had a successful first quarter with an all-around beat. The company executed the launch of Leqembi, an immediate transformative product in...

Baptista Research

CSL Ltd (CSL AU): Looking into New Engines for Sustainable and Profitable Growth

New management, upcoming product launch in US, diversification into kidney disease, plasma collection recovery, and rich pipeline indicate an...

Tina Banerjee

Biogen Inc.: Major Drivers

Biogen delivered an all-around beat in the last result. TECFIDERA generic competition, ongoing interferon declines and some pricing pressure...

Baptista Research

Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts

Upcoming participation in healthcare conference, Q4 result, and biosimilar launch in US are key catalysts to watch. Ongoing capex amid strong order...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)